Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialPepijn Eijsvogel, Jean‐Cosme Dodart, Shuang Ding et al.|Nature Medicine|2024Cited by 38
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravisMartin Skov, Thomas Holm Pedersen, Titia Q. Ruijs et al.|Science Translational Medicine|2024Cited by 31